drugset / Trial / NCT04231513

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

NCT04231513

Phase 1 Completed 72 enrolled Eisai Inc.
RandomizedSequentialDouble-blindOther

Summary

The primary objective of this study is to evaluate the safety and tolerability of single and multiple intravenous infusions of E2814 in healthy adult participants.

Timeline

Start
2019-12-16
Primary completion
2023-03-09
Completion
2023-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Etalanetug Monoclonal antibody Intravenous

Indications

No indication recorded.